Skip to main content
Top
Published in: Familial Cancer 3/2017

01-07-2017 | Original Article

Novel and reported pathogenic variants in exon 11 of BRCA2 gene in a cohort of Sri Lankan young breast cancer patients

Authors: Sumadee De Silva, Kamani Hemamala Tennekoon, Aravinda Dissanayake, Kanishka De Silva, Lakshika Jayasekara

Published in: Familial Cancer | Issue 3/2017

Login to get access

Abstract

Women with breast carcinoma diagnosed before 40 years of age with a strong familial risk have a greater prevalence of germline BRCA1 or BRCA2 variants than late onset breast cancer. Previously germline variants in BRCA1 and BRCA2 genes were characterized in a cohort of Sri Lankan breast cancer patients unselected for age of onset. This study focused on young breast cancer patients who were screened for previously identified hotspot regions in BRCA2 gene. A total of 48 young breast cancer patients with family history of cancer and 25 healthy controls were studied. Direct sequencing was used to detect pathogenic and other sequence variants in the hotspot regions of BRCA2 gene. Thirty-six sequence variants including seven pathogenic (c.2411_2412delAA/p.Glu804Valfs*2, c.2500_2501insG/p.Leu834Cysfs*4, c.3881T>G/p.Leu1294*, c.4768A>T/p.Lys1590*, c.5645C>G/p.Ser1882*, c.5747delC/p.His1916Phefs*3, c.6728C>T/p.Ser2243Phe) and two likely pathogenic (c.1922C>T and c.3378A>T) variants, two intronic variants of unknown significance (c.1910-74T>C, c.1910-51G>T), two variants of uncertain significance (c.2324C>T c.5104C>T) and 23 benign variants were detected. Among them, seven were novel (pathogenic 5 and likely pathogenic 2). Prevalence of pathogenic and likely pathogenic variants in the hotspots regions of BRCA2 was 23 and 6.3 % respectively in this cohort. This justifies BRCA2 variant testing in young breast cancer patients with family history of cancer in Sri Lanka.
Literature
2.
go back to reference Al-Ansari A, Al-Mawali K, Al-Bahrani B, Al-Moundhri MS (2013) BRCA1 gene molecular alterations in omani breast cancer patients. Gulf J Oncolog 1(14):45–51PubMed Al-Ansari A, Al-Mawali K, Al-Bahrani B, Al-Moundhri MS (2013) BRCA1 gene molecular alterations in omani breast cancer patients. Gulf J Oncolog 1(14):45–51PubMed
3.
go back to reference Keegan THM, Press DJ, Tao L, DeRouen MC, Kurian AW, Clarke CA, Gomez SL (2013) Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res 15(5):R95CrossRefPubMedPubMedCentral Keegan THM, Press DJ, Tao L, DeRouen MC, Kurian AW, Clarke CA, Gomez SL (2013) Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res 15(5):R95CrossRefPubMedPubMedCentral
4.
go back to reference Armes JE, Egan AJM, Southey MC, Dite GS, McCredie MRE, Giles GG, Hopper JL, Venter DJ (1998) The histologic phenotypes of breast carcinoma occurring before Age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 83(11):2335–2345CrossRefPubMed Armes JE, Egan AJM, Southey MC, Dite GS, McCredie MRE, Giles GG, Hopper JL, Venter DJ (1998) The histologic phenotypes of breast carcinoma occurring before Age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 83(11):2335–2345CrossRefPubMed
7.
go back to reference Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, McLennan J, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA (2011) Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 104(9):1384–1392. doi:10.1038/bjc.2011.120 CrossRefPubMedPubMedCentral Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, McLennan J, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA (2011) Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 104(9):1384–1392. doi:10.​1038/​bjc.​2011.​120 CrossRefPubMedPubMedCentral
8.
go back to reference Cancer Registry (2010) National Cancer Control Programme, Government Cancer Institute, Cancer Incidence Data, Maharagama Cancer Registry (2010) National Cancer Control Programme, Government Cancer Institute, Cancer Incidence Data, Maharagama
9.
go back to reference Cancer Registry (2009) National Cancer Control Programme, Government Cancer Institute: Cancer Incidence Data, Maharagama Cancer Registry (2009) National Cancer Control Programme, Government Cancer Institute: Cancer Incidence Data, Maharagama
10.
11.
go back to reference De Silva S, Tennekoon KH, Karunanayake EH, De Silva W, Amarasinghe I, Angunawala P (2011) Novel sequence variants and common recurrent polymorphisms of BRCA2 in Sri Lankan breast cancer patients and a family with BRCA1 mutations. Exp Ther Med 2 (6):1163–1170 De Silva S, Tennekoon KH, Karunanayake EH, De Silva W, Amarasinghe I, Angunawala P (2011) Novel sequence variants and common recurrent polymorphisms of BRCA2 in Sri Lankan breast cancer patients and a family with BRCA1 mutations. Exp Ther Med 2 (6):1163–1170
12.
go back to reference De Silva W, Karunanayake EH, Tennekoon KH, Allen M, Amarasinghe I, Angunawala P, Ziard MH (2008) Novel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals. BMC Cancer 8:214. doi:10.1186/1471-2407-8-214 CrossRefPubMedPubMedCentral De Silva W, Karunanayake EH, Tennekoon KH, Allen M, Amarasinghe I, Angunawala P, Ziard MH (2008) Novel sequence variants and a high frequency of recurrent polymorphisms in BRCA1 gene in Sri Lankan breast cancer patients and at risk individuals. BMC Cancer 8:214. doi:10.​1186/​1471-2407-8-214 CrossRefPubMedPubMedCentral
13.
go back to reference Kwong A, Shin VY, Ho JC, Kang E, Nakamura S, Teo SH, Lee AS, Sng JH, Ginsburg OM, Kurian AW, Weitzel JN, Siu MT, Law FB, Chan TL, Narod SA, Ford JM, Ma ES, Kim SW (2016) Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. J Med Genet 53(1):15–23. doi:10.1136/jmedgenet-2015-103132 CrossRefPubMed Kwong A, Shin VY, Ho JC, Kang E, Nakamura S, Teo SH, Lee AS, Sng JH, Ginsburg OM, Kurian AW, Weitzel JN, Siu MT, Law FB, Chan TL, Narod SA, Ford JM, Ma ES, Kim SW (2016) Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries. J Med Genet 53(1):15–23. doi:10.​1136/​jmedgenet-2015-103132 CrossRefPubMed
15.
go back to reference Miller SA, Dykes DD, Poleskey HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):12–15CrossRef Miller SA, Dykes DD, Poleskey HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):12–15CrossRef
16.
go back to reference Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL (2015) ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424. doi:10.1038/gim.2015.30 CrossRefPubMedPubMedCentral Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL (2015) ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–424. doi:10.​1038/​gim.​2015.​30 CrossRefPubMedPubMedCentral
17.
go back to reference Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL and the CIMBA Consortium (2015) Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13):1347–1361. doi:10.1001/jama.2014.5985 CrossRefPubMedPubMedCentral Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL and the CIMBA Consortium (2015) Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13):1347–1361. doi:10.​1001/​jama.​2014.​5985 CrossRefPubMedPubMedCentral
18.
go back to reference Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Mochizuki H, Omata M (2015) Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol Genet Genomic Med 3(2):121–129. doi:10.1002/mgg3.120 CrossRefPubMed Hirotsu Y, Nakagomi H, Sakamoto I, Amemiya K, Mochizuki H, Omata M (2015) Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. Mol Genet Genomic Med 3(2):121–129. doi:10.​1002/​mgg3.​120 CrossRefPubMed
19.
20.
go back to reference Caputo S, Benboudjema L, Sinilnikova O, Rouleau E, Béroud C, Lidereau R; French BRCA GGC Consortium (2012) Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. Nucleic Acids Res 40(Database issue):D992–1002. doi:10.1093/nar/gkr1160 CrossRefPubMed Caputo S, Benboudjema L, Sinilnikova O, Rouleau E, Béroud C, Lidereau R; French BRCA GGC Consortium (2012) Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. Nucleic Acids Res 40(Database issue):D992–1002. doi:10.​1093/​nar/​gkr1160 CrossRefPubMed
21.
go back to reference Pohlreich P, Zikan M, Stribrna J, Kleibl Z, Janatova M, Kotlas J, Zidovska J, Novotny J, Petruzelka L, Szabo C, Matous B (2005) High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res 7(5):R728–R736CrossRefPubMedPubMedCentral Pohlreich P, Zikan M, Stribrna J, Kleibl Z, Janatova M, Kotlas J, Zidovska J, Novotny J, Petruzelka L, Szabo C, Matous B (2005) High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res 7(5):R728–R736CrossRefPubMedPubMedCentral
22.
go back to reference Kim H, Cho DY, Choi DH, Choi SY, Shin I, Park W, Huh SJ, Han SH, Lee MH, Ahn SH, Son BH, Kim SW, Korean Breast Cancer Study Group, Haffty BG (2012) Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3922 Korean patients with breast and ovarian cancer. Breast Cancer Res Treat 134(3):1315–1326. doi:10.1007/s10549-012-2159-5 CrossRefPubMed Kim H, Cho DY, Choi DH, Choi SY, Shin I, Park W, Huh SJ, Han SH, Lee MH, Ahn SH, Son BH, Kim SW, Korean Breast Cancer Study Group, Haffty BG (2012) Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3922 Korean patients with breast and ovarian cancer. Breast Cancer Res Treat 134(3):1315–1326. doi:10.​1007/​s10549-012-2159-5 CrossRefPubMed
Metadata
Title
Novel and reported pathogenic variants in exon 11 of BRCA2 gene in a cohort of Sri Lankan young breast cancer patients
Authors
Sumadee De Silva
Kamani Hemamala Tennekoon
Aravinda Dissanayake
Kanishka De Silva
Lakshika Jayasekara
Publication date
01-07-2017
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2017
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-016-9962-9

Other articles of this Issue 3/2017

Familial Cancer 3/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine